Ann: Update on Nasdaq Listing, page-136

Hi C, I'm a latecomer to this company but very excited on where its heading. Just bought in recently after I lucked out with other stocks. Been researching a lot about their patents especially for Obstructive Sleep Apneoa as that is a game changer in medical treatment. Never before has any company treated OSA by pharmaceuticals / cannabinoids so I expect US investor interest will be strong on this alone !

IHL-42X is a novel combination therapy that combines the cannabinoid-based dronabinol with the inhibitor acetazolamide with the aim of achieving improved health outcomes for OSA – the most common sleep-related breathing disorder globally that has no pharmaceutical treatment option.

NASDAQ here we come